Information, not a decision

Liver and biliary tract cancer: tumour board sheet

Dated public registry data. It contains no treatment recommendation. 15 Nov 2026

Open trials (1509)

NCT07488676	Phase 1/2	A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors	Recruiting
NCT06698250	Phase 2	Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)	Recruiting
NCT07715903	Phase 1	Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy	Not yet recruiting
NCT06434480	No phase	SBRT in HCC With Oligoprogression on First-line Immunotherapy	Recruiting
NCT07933016	Phase 2	QL1706 and Lenvatinib Combined With FOLFOX Systemic Chemotherapy as Second-line Treatment in Advanced Hepatocellular Carcinoma Patients	Not yet recruiting
NCT07458347	Phase 1	A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation	Recruiting
NCT07197554	Phase 1	A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies	Recruiting
NCT04907643	No phase	Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes	Recruiting
NCT06270706	Phase 1	A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors	Recruiting
NCT07118202	No phase	TheraBionic P1 Device in Subjects With Advanced Hepatocellular Carcinoma	Recruiting
NCT06420440	Phase 2	Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model	Recruiting
NCT05053555	No phase	High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies	Recruiting

1497 more in the doctor's list on the site.

Phase 3 trials that ended in the last 90 days

2023-503229-21-00	20 Oct 2026	A Study of Atezolizumab with Lenvatinib or Sorafenib versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated with Atezolizumab and Bevacizumab	Completed
2023-508726-10-00	28 Sept 2026	A Phase 3 Study of Nivolumab versus Placebo for Participants with Hepatocellular Cancer Who Are at High Risk of Recurrence after Hepatic Resection or Ablation	Completed

Guidelines

Links only: read the guideline itself.

Made from the public data of Frontlight Research. Source: ClinicalTrials.gov, EU CTIS. 15 Nov 2026

https://frontlightresearch.com/en/doctor/liver-and-biliary-cancer/tumor-board